Phase 1 study of cabozantinib in combination with topotecan-cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma
CONCLUSIONS: The recommended phase 2 doses and schedules for this combination are topotecan 0.75 mg/m2 IV days 1-5, cyclophosphamide 250 mg/m2 IV days 1-5, and cabozantinib 25 mg/m2 days 8-21. Non-concomitant administration of cabozantinib with cytotoxic therapy in this population has acceptable toxicity, while allowing for potential disease control.PMID:37715723 | DOI:10.1002/pbc.30681 (Source: Cancer Control)
Source: Cancer Control - September 16, 2023 Category: Cancer & Oncology Authors: Kevin Campbell Andrew Posner Nan Chen Kerri Cavanaugh Ketki Bhushan Katherine A Janeway David S Shulman Suzanne George Kelly Klega Brian Crompton Wendy B London Steven G DuBois Source Type: research
Identifying racial disparities in hereditary hemorrhagic telangiectasia
Conclusion
Patients who identified as Asian may have higher rates of pulmonary AVMs while patients identifying as Hispanic or Latino may have more cerebral AVMs. The correlations may be important for identifying risk factors in certain patient populations. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - September 15, 2023 Category: Neurosurgery Authors: Yusuf, H., Rasheed, A., Kim, H., Conrad, M. B., Hetts, S. W. Tags: Socioeconomics Source Type: research
Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data
Conclusions
Analyses of the ASCEND randomised trial found that major bleeding events ascertained via UK routine data sources provided relative and absolute treatment effects similar to adjudicated follow-up.
Trial registration number
ISRCTN60635500; NCT00135226. (Source: Heart)
Source: Heart - September 13, 2023 Category: Cardiology Authors: Harper, C., Mafham, M., Herrington, W., Staplin, N., Stevens, W., Wallendszus, K., Haynes, R., Landray, M. J., Parish, S., Bowman, L., Armitage, J. Tags: Open access Study design Source Type: research
Silicone septal splint for recurrent epistaxis in HHT patients: experience of a national referral centre
CONCLUSIONS: In HHT patients with recurrent severe epistaxis and with septal perforation, the placement of septal splints offers a useful additional strategy in the management of nosebleeds.PMID:37698097 | PMC:PMC10159634 | DOI:10.14639/0392-100X-suppl.1-43-2023-03 (Source: Acta Otorhinolaryngologica Italica)
Source: Acta Otorhinolaryngologica Italica - September 12, 2023 Category: ENT & OMF Authors: Elina Matti Eugenia Maiorano Bogdan Nacu Andrea Luceri Fabio Sovardi Vera Siragusa Anna Ferrauto Giuseppe Spinozzi Carla Olivieri Marco Benazzo Fabio Pagella Source Type: research
